Sirolimus and cardiovascular disease risk in liver transplantation

Transplantation

Volumn 95, Issue 1, 2013, Pages 215-221

  McKenna, Greg J ^a,b   Trotter, James F ^a,b   Klintmalm, Erik ^a,b   Ruiz, Richard ^a,b   Onaca, Nicholas ^a,b   Testa, Giuliano ^a,b   Saracino, Giovanna ^a,b   Levy, Marlon F ^a,b   Goldstein, Robert M ^a,b   Klintmalm, Goran B ^a,b  

^a Annette C and Harold C Simmons Transplant Institute   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Framingham Risk Model; Framingham Risk Score; mTOR inhibitor inhibition; Sirolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; ADULT; ANEMIA; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; CANDIDIASIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLANGITIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COLITIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG FATALITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; FRACTURE; FRAMINGHAM RISK SCORE; GRAFT RECIPIENT; HEART INFARCTION; HEPATIC ARTERY THROMBOSIS; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DYSFUNCTION; LIPOPROTEIN BLOOD LEVEL; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; NEUTROPENIA; PANCREATITIS; PNEUMONIA; PORTAL VEIN THROMBOSIS; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRIGLYCERIDES;

EID: 84872069888     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318279090c     Document Type: Article

References (32)

1. Adelman S. Sirolimus and its analogs and its effects on vascular diseases. Curr Pharm Des 2010; 16: 4002.
2. Ross R. AtherosclerosisVan inflammatory disease. N Engl J Med 1999; 340: 115.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868.
4. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action of immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335.
5. Ma KL, Varghese Z, Ku Y, et al. Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2010; 298: H1646.
6. Ma KL, Ruan XZ, Powis SH, et al. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscles cells. Am J Physiol Heart Circ Physiol 2007; 292: H2721.
7. Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3: 562.
8. Morales JM. Cardiovascular risk profile in patients treated with sirolimus after renal transplantation. Kidney Int Suppl 2005; 93: S69.
9. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2: 551.
10. Fellstrom B. Risk factors for management of post-transplantation cardiovascular disease. Biodrugs 2001; 15: 261.
11. Kasiska BL, Guijaro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
12. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853.
13. Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids. Circulation 2005; 112: 3184.
14. Zhao L, Ding T, Cyrus T, et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. Br J Pharmacol 2009; 156: 774.
15. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 2005; 98: 2277.
16. Castro C, Campistol JM, Sancho D, et al. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway. Atherosclerosis 2004; 172: 31.
17. Pakala R, Stabile E, Jang GJ, et al. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharm2005; 46: 481.
18. Mathis AS, Jin S, Friedman GS, et al. The pharmacodynamics effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors. J Pharm Sci 2007; 96: 209.
19. Cizek SM, Bedri S, Talusan P, et al. Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia. Cardiovasc Pathol 2007; 16: 344.
20. Martin KA, Rzucidlo EM, Merenick BL, et al. The mTOR/p70/S6k1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 2004; 286: C507.
21. Morris RE, Cao W, Huang X, et al. Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and non-immune cells. Transplant Proc 1995; 27: 430.
22. Diez-Juan A, Andres V. The growth suppressor p27 (Kip1) protects against diet-induced atherosclerosis. FASEB J 2001; 11: 1989.
23. Gregory CR, Huie P, Billingham ME, et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effects on cellular, growth factor, and cytokine responses in injured vessels. Transplantation 1993; 55: 1409.
24. Burke SE, Lubbers NL, Chen YW, et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 1999; 33: 829.
25. Heim C, Abele-Ohi S, Eckl S, et al. Murine cytomegalovirus infection leads to increased levels of transplant arteriosclerosis in a murine aortic allograft model. Transplantation 2010; 90: 373.
26. Persoons MC, Daemen MJ, Bruning JH, et al. Active cytomegalovirus infection of arterial smooth muscle cells in immunocompromised rats. A clue to herpesvirus-associated atherogenesis. Circ Res 1994; 75: 214.
27. Epstein SE, Speir E, Zhou YF, et al. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996; 348: 13.
28. Zhou YF, Keon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. New Engl J Med 1996; 335: 625.
29. Moorman NJ, Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010; 84: 5260.
30. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitorYbased immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075.
31. Chatterjee K, Zhang J, Honbo N, et al. Doxorubicin cardiomyopathy. Cardiology 2010; 115: 155.
32. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743.